Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain

被引:44
|
作者
Unzue, Andrea [1 ]
Xu, Min [2 ]
Dong, Jing [2 ]
Wiedmer, Lars [2 ]
Spiliotopoulos, Dimitrios [2 ]
Caflisch, Amedeo [2 ]
Nevado, Cristina [1 ]
机构
[1] Univ Zurich, Dept Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland
[2] Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
ACETYL-LYSINE INTERACTIONS; SMALL-MOLECULE INHIBITORS; ACUTE MYELOID-LEUKEMIA; BINDING-PROTEIN; DISCOVERY; OPTIMIZATION; ACETYLTRANSFERASE; CBP/P300; I-BET762; THERAPY;
D O I
10.1021/acs.jmedchem.5b00172
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Novel ligands of the CREBBP bromodomain were identified by fragment-based docking. The in silico discovered hits have been optimized by chemical synthesis into selective nanomolar compounds, thereby preserving the ligand efficiency. The selectivity for the CREBBP bromodomain over other human bromodomain subfamilies has achieved by a benzoate moiety which was predicted by docking to be involved in favorable electrostatic interactions with the Arg1173 side chain, a prediction that could be verified a posteriori by the high-resolution crystal structure of the CREBBP bromodomain in complex with ligand 6 and also by MD simulations (see Xu, M.; Unzue, A.; Dong, J.; Spiliotopoulos, D.; Nevado, C.; Caflisch, A. Discovery of CREBBP bromodomain inhibitors by high throughput docking and hit optimization guided by molecular dynamics. J. Med. Chem. 2015, DOI: 10.1021/acs.jmedchem.51300171).
引用
收藏
页码:1350 / 1356
页数:7
相关论文
共 50 条
  • [31] Puzzling through fragment-based drug design
    Hajduk, Philip J.
    [J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (12) : 658 - 659
  • [32] Fragment-based QSAR strategies in drug design
    Salum, Livia B.
    Andricopulo, Adriano D.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (05) : 405 - 412
  • [33] Comptational methods in fragment-based drug design
    Williams, Chris
    Leonard, Joseph M.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [34] Fragment-based QSAR: perspectives in drug design
    Lívia B. Salum
    Adriano D. Andricopulo
    [J]. Molecular Diversity, 2009, 13 : 277 - 285
  • [35] Puzzling through fragment-based drug design
    Philip J Hajduk
    [J]. Nature Chemical Biology, 2006, 2 : 658 - 659
  • [36] Supramolecular engineering via fragment-based design
    Hay, Benjamin
    McCann, Billy Wayne
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [37] Genetically-encoded fragment-based discovery of glycomimetic ligands
    Derda, Ratmir
    Ng, Simon
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [38] Ligand Specificity in Fragment-Based Drug Design
    Barelier, Sarah
    Pons, Julien
    Gehring, Kalle
    Lancelin, Jean-Marc
    Krimm, Isabelle
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) : 5256 - 5266
  • [39] Protein crystallography and fragment-based drug design
    Caliandro, Rocco
    Belviso, Danilo Benny
    Aresta, Brunella Maria
    de Candia, Modesto
    Altomare, Cosimo Damiano
    [J]. FUTURE MEDICINAL CHEMISTRY, 2013, 5 (10) : 1121 - 1140
  • [40] Structural biology in fragment-based drug design
    Murray, Christopher W.
    Blundell, Tom L.
    [J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 2010, 20 (04) : 497 - 507